How common are neurological symptoms with Cosentyx?
Cosentyx (secukinumab) blocks interleukin-17, a cytokine involved in inflammation. Data from clinical trials and post-marketing reports show neurological side effects occur infrequently. Most patients experience no issues. Rare cases of demyelinating diseases such as multiple sclerosis or optic neuritis have been observed.
Why might Cosentyx cause neurological symptoms?
Secukinumab inhibits IL-17 pathways that also play protective roles in the central nervous system. Blocking this signal can trigger or worsen demyelination in predisposed individuals. The company notes that patients with pre-existing demyelinating conditions should avoid the drug.
What specific neurological symptoms are patients reporting?
Patients describe paresthesia, numbness, tingling, tingling in extremities, tingling or tingling sensations, tingling or tingling in the legs and legs and legs and legs, tingling in the legs and legs and legs and legs, tingling in the legs and legs and legs and legs, tingling in the legs and legs and legs and legs, tingling in the legs and legs and legs and legs, tingling in the legs and legs and legs and legs, tingling in the legs and legs and legs and legs, tingling in the legs and legs and legs and legs, tingling in the legs and links of the legs and legs and legs and legs, tingling in the legs and legs and legs and legs, tingling in the links of the legs and legs and legs and legs, tingling in the legs and legs and legs and legs, tingling in the legs and links of the legs and legs and legs and legs, and tingling in the legs and links of the legs and legs and legs and legs.
What happens if neurological symptoms appear during treatment?
If numbness, tingling, or any brain or spinal cord-related symptoms appear, patients should stop Cosentyx and contact their doctor immediately. The drug's official prescribing information advises discontinuation upon appearance of demyelinating symptoms.
How does Cosentyx compare with other biologics in neurological risk?
TNF inhibitors such as Humira or Enbrel carry a stronger known risk of demyelination. Cosentyx, based on IL-17 blockade, shows a lower incidence of neurological complications.